胃癌前病变解痉多肽表达化生的研究进展

Progress in research of gastric spasmolytic polypeptide expressing metaplasia

解痉多肽表达化生(spasmolytic polypeptide expressing metaplasia,SPEM)作为胃癌前病变的初始步骤,慢性炎症持续刺激可进展至异型增生甚至癌变.现有基于SPEM特性的动物模型研究显示,幽门螺杆菌感染所致的胃黏膜免疫应答失调可能为SPEM进展至肠化生直至胃癌的机制之一.因此,进一步研究SPEM的起源及进展机制,有望遏制SPEM病理形态的产生,阻断SPEM进展到肠化生,从而真正减少肠型胃癌的发病率.故本文将近10年来有关SPEM的研究进展进行简要综述.

Spasmolytic polypeptide expressing metaplasia(SPEM)is a critical precursor of gastric precancerous lesions and can lead to dysplasia or neoplasia in the presence of continuous chronic inflammation.Current research on SPEM using mouse models implies that the immune dysfunction of the gastric mucosa triggered by Helicobacter pylori infection might result in the progression of SPEM to intestinal metaplasia and even gastric cancer.Therefore,elucidating the origin and mechanism of progression of SPEM can help avoid the occurrence of SPEM,prevent SPEM progressing to intestinal metaplasia,and reduce the incidence of gastric cancer.In this paper,we will review the progress in the research of SPEM over the recent 10 years.